Similar articles

• Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

  Terris MK. Terris MK. Eur Urol. 2009 Feb;55(2):392; discussion 393. doi: 10.1016/j.eururo.2008.02.047. Epub 2008 Mar 11. Eur Urol. 2009. PMID: 18353530 No abstract available.
• Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.

  Shteynshlyuger A, Andriole GL. Shteynshlyuger A, et al. J Urol. 2011 Mar;185(3):828-32. doi: 10.1016/j.juro.2010.10.079. Epub 2011 Jan 15. J Urol. 2011. PMID: 21239021
• Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.

  Connolly D, Hutton R, Keane PF. Connolly D, et al. Eur Urol. 2011 Mar;59(3):e9; author reply e10-1. doi: 10.1016/j.eururo.2010.11.035. Epub 2010 Dec 4. Eur Urol. 2011. PMID: 21145647 No abstract available.
• The story of the European Randomized Study of Screening for Prostate Cancer.

  Schröder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, Villers A, Rebillard X, Ciatto S, Zappa M, Berenguer A, Paez A, Hugosson J, Lodding P, Recker F, Kwiatkowski M, Kirkels WJ; ERSPC. Schröder FH, et al. BJU Int. 2003 Dec;92 Suppl 2:1-13. doi: 10.1111/j.1464-410x.2003.04389.x. BJU Int. 2003. PMID: 14983946 Review. No abstract available.
• No randomised trial of prostate-cancer screening in Norway.

  Fosså SD, Eri LM, Skovlund E, Tveter K, Vatten L; Norwegian Urological Cancer Group. Fosså SD, et al. Lancet Oncol. 2001 Dec;2(12):741-5; discussion 746-9. doi: 10.1016/S1470-2045(01)00588-5. Lancet Oncol. 2001. PMID: 11902516 Review.